- Home
- SCPH vs PVLA Comparison
SCPH vs PVLA Comparison
Compare SCPH & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- PVLA
- Stock Information
- Founded
- SCPH 2013
- PVLA 2015
- Country
- SCPH United States
- PVLA United States
- Employees
- SCPH N/A
- PVLA N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- PVLA Health Care
- Exchange
- SCPH Nasdaq
- PVLA Nasdaq
- Market Cap
- SCPH 299.0M
- PVLA 285.2M
- IPO Year
- SCPH 2017
- PVLA N/A
- Fundamental
- Price
- SCPH $5.63
- PVLA $56.84
- Analyst Decision
- SCPH Buy
- PVLA Strong Buy
- Analyst Count
- SCPH 3
- PVLA 12
- Target Price
- SCPH $12.00
- PVLA $59.00
- AVG Volume (30 Days)
- SCPH 2.3M
- PVLA 123.6K
- Earning Date
- SCPH 11-12-2025
- PVLA 08-14-2025
- Dividend Yield
- SCPH N/A
- PVLA N/A
- EPS Growth
- SCPH N/A
- PVLA N/A
- EPS
- SCPH N/A
- PVLA N/A
- Revenue
- SCPH $49,969,000.00
- PVLA N/A
- Revenue This Year
- SCPH $108.95
- PVLA N/A
- Revenue Next Year
- SCPH $78.30
- PVLA N/A
- P/E Ratio
- SCPH N/A
- PVLA N/A
- Revenue Growth
- SCPH 107.79
- PVLA N/A
- 52 Week Low
- SCPH $1.94
- PVLA $11.17
- 52 Week High
- SCPH $6.28
- PVLA $61.48
- Technical
- Relative Strength Index (RSI)
- SCPH 64.37
- PVLA 64.06
- Support Level
- SCPH $4.33
- PVLA $49.81
- Resistance Level
- SCPH $5.62
- PVLA $61.48
- Average True Range (ATR)
- SCPH 0.05
- PVLA 4.43
- MACD
- SCPH 0.01
- PVLA -0.19
- Stochastic Oscillator
- SCPH 93.75
- PVLA 62.41
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.